GlycoMimetics Files 8-K for Financial Statements and Exhibits

Ticker: CBIO · Form: 8-K · Filed: Jun 4, 2024 · CIK: 1253689

Glycomimetics INC 8-K Filing Summary
FieldDetail
CompanyGlycomimetics INC (CBIO)
Form Type8-K
Filed DateJun 4, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: financial-statements, exhibits, sec-filing

Related Tickers: GLYC

TL;DR

GlycoMimetics dropped an 8-K with financial updates. Check it out.

AI Summary

On June 4, 2024, GlycoMimetics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating updates or disclosures related to the company's financial condition and operations. No specific material events or transactions are detailed in the provided excerpt.

Why It Matters

This filing provides updated financial information and exhibits for GlycoMimetics, Inc., which is crucial for investors and stakeholders to assess the company's financial health and operational status.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any immediate material adverse events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by GlycoMimetics, Inc.?

The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the 'ITEM INFORMATION' section.

On what date was this 8-K report filed?

The report was filed on June 4, 2024.

In which state is GlycoMimetics, Inc. incorporated?

GlycoMimetics, Inc. is incorporated in Delaware.

What is the address of GlycoMimetics, Inc.'s principal executive offices?

The address of the principal executive offices is 9708 Medical Center Drive, Rockville, MD 20850.

Does this filing indicate any specific material events or transactions?

Based on the provided excerpt, the filing is categorized under 'Regulation FD Disclosure' and 'Financial Statements and Exhibits,' and does not detail specific material events or transactions.

Filing Stats: 602 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-06-04 09:30:15

Key Financial Figures

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On June 4, 2024, GlycoMimetics, Inc. (the " Company ") issued a press release announcing comprehensive results from its pivotal Phase 3 clinical trial of uproleselan in patients with relapsed/refractory acute myeloid leukemia. On June 4, 2024, the Company also hosted a live webcast to discuss the results. The press release and slide presentation used during the webcast are attached as Exhibits 99.1 and 99.2, respectively, to this Current Report and are incorporated herein solely for purposes of this Item 7.01 disclosure. The information in this Item 7.01, including the exhibits attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended (the " Securities Act ") or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such filing, except as otherwise expressly stated in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits 9, Exhibit Number Exhibit Description 99.1 Press release, dated June 4, 2024, "GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)." 99.2 Corporate Presentation, June 4, 2024. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GLYCOMIMETICS, INC. By: /s/ Brian M. Hahn Date: June 4, 2024 Brian M. Hahn Senior Vice President and Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing